Exploring Induction and Maintenance Regimens for Older Patients With AML

This activity was originally presented live at the 2022 Asembia Specialty Pharmacy Summit.

This activity features a Patient Perspective.

Program Description

Treatment considerations for older patients with acute myeloid leukemia (AML) can be influenced by mutation status as well as impairment of physical or cognitive function. Older patients with AML experience high relapse rates leading to poor outcomes, but recent approvals, such as oral hypomethylating agents and combination therapies, in AML maintenance therapy have expanded treatment options and administration routes for older patients who are not able to complete intensive therapy. Pharmacists practicing on the multidisciplinary team in caring for older patients with AML must be familiar with recently approved and investigational treatment strategies. This activity will examine clinical outcomes and guideline recommendations for first-line and maintenance therapies in older patients with AML. As additional agents enter clinical trials or become approved for AML, specialty pharmacists will need to be involved in establishing evidence-based treatment protocols to deliver patient-specific care and reduce financial burden. Expert faculty will also discuss challenges specific to older patients, including mutational and functional status of patients in determining treatment eligibility and supportive care needs.

Target audience: Oncology pharmacists and specialty pharmacists

Type of activity: Application
Release date: May 10, 2022
Expiration date: May 10, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify the clinical data and rationale for newly approved and emerging alternative induction regimens for patients with acute myeloid leukemia (AML)
• Explain challenges associated with the use of agents indicated for maintenance therapy for older patients with AML
• Apply tactics to overcome treatment challenges in older patients with AML

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-220-H01-P. The activity is available for CE credit through May 10, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Megan Rees, PharmD, BCACP, CSP, and Anthony J. Perissinotti, PharmD, BCOP, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff— Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

Medical Reviewer: Madeline Waldron, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Sanofi, SeaGen

Speakers Bureau: AstraZeneca

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms